MYC is a transcription factor controlling growth and nutrient metabolism. Luo et al. now link intestinal expression of MYC to impairments in glucose, lipid and body-weight homeostasis by uncovering novel roles of MYC in regulating the glucagon-like peptide GLP1 and the ceramide-biosynthesis regulator CERS4. Myc deletion in the intestinal epithelium prevents or reverses diet-induced obesity and hepatic steatosis in mice. Critically, people with obesity display elevated MYC and CERS4 expression in the ileum, thus further supporting the clinical relevance of these findings.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Choi, R. H., Tatum, S. M., Symons, J. D., Summers, S. A. & Holland, W. L. Nat. Rev. Cardiol. 45, 101145 (2021).
Xia, J. Y. et al. Cell Metab. 22, 266–278 (2015).
Holland, W. L. et al. Mol. Metab. 6, 267–275 (2017).
Luo, Y. et al. Nat. Metab. https://doi.org/10.1038/s42255-021-00421-8 (2021).
Holland, W. L. et al. Cell Metab. 5, 167–179 (2007).
Jiang, C. et al. J. Clin. Invest. 125, 386–402 (2015).
Jiang, C. et al. Nat. Commun. 6, 10166 (2015).
Xie, C. et al. Diabetes 66, 613–626 (2017).
Xie, C. et al. Nat. Med. 23, 1298–1308 (2017).
Chaurasia, B. et al. Mol. Metab. 45, 101145 (2021).
Li, Z. et al. Cell Death Dis. 9, 173 (2018).
Acknowledgements
The authors received research support from the US National Institutes of Health (DK115824, DK116888 and DK116450 to S.A.S.; DK112826 to W.L.H.), the Juvenile Diabetes Research Foundation (JDRF 3-SRA-2019-768-A-B to S.A.S.), the American Diabetes Association (to S.A.S.), the American Heart Association (to S.A.S.) and the Margolis Foundation (to S.A.S.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.A.S. is a consultant, co-founder and shareholder of Centaurus Therapeutics. The other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Li, Y., Summers, S.A. & Holland, W.L. Gutting out Myc to decrease ceramides. Nat Metab 3, 890–891 (2021). https://doi.org/10.1038/s42255-021-00418-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s42255-021-00418-3